These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33544072)

  • 1. Validation of the Prevention Impacts Simulation Model (PRISM).
    Yarnoff B; Honeycutt A; Bradley C; Khavjou O; Bates L; Bass S; Kaufmann R; Barker L; Briss P
    Prev Chronic Dis; 2021 Feb; 18():E09. PubMed ID: 33544072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategic Planning for Chronic Disease Prevention in Rural America: Looking Through a PRISM Lens.
    Honeycutt AA; Wile K; Dove C; Hawkins J; Orenstein D
    J Public Health Manag Pract; 2015; 21(4):392-9. PubMed ID: 25084535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.
    Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
    Value Health; 2012; 15(6):843-50. PubMed ID: 22999134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of simulation models in health economic evaluation studies of dietary salt-reduction policies for cardiovascular disease prevention].
    Kato H; Ikeda N; Sugiyama T; Nomura M; Yoshita K; Nishi N
    Nihon Koshu Eisei Zasshi; 2021 Sep; 68(9):631-643. PubMed ID: 34261839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.
    Ekpu VU; Brown AK
    Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Simulation Modeling to Inform Decision Making for Health Care Systems and Policy in Colorectal Cancer Screening: Protocol for a Systematic Review.
    Smith H; Varshoei P; Boushey R; Kuziemsky C
    JMIR Res Protoc; 2020 May; 9(5):e16103. PubMed ID: 32401223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selecting a dynamic simulation modeling method for health care delivery research-part 2: report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force.
    Marshall DA; Burgos-Liz L; IJzerman MJ; Crown W; Padula WV; Wong PK; Pasupathy KS; Higashi MK; Osgood ND;
    Value Health; 2015 Mar; 18(2):147-60. PubMed ID: 25773550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
    Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
    Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7.
    Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
    Med Decis Making; 2012; 32(5):733-43. PubMed ID: 22990088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of population-based disease simulation models: a review of concepts and methods.
    Kopec JA; Finès P; Manuel DG; Buckeridge DL; Flanagan WM; Oderkirk J; Abrahamowicz M; Harper S; Sharif B; Okhmatovskaia A; Sayre EC; Rahman MM; Wolfson MC
    BMC Public Health; 2010 Nov; 10():710. PubMed ID: 21087466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force.
    Crown W; Buyukkaramikli N; Sir MY; Thokala P; Morton A; Marshall DA; Tosh JC; Ijzerman MJ; Padula WV; Pasupathy KS
    Value Health; 2018 Sep; 21(9):1019-1028. PubMed ID: 30224103
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.